Straumann Holding AGXSWX:STMN +1.65%100 Cyclically Adjusted PB Ratio is 11.12 as of Jul. 05, 2026, which is 33% below its 10-year median of 16.48. GuruFocus rates XSWX:STMN with a GF Score™ of 100/100 and a GF Value™ of CHF137.24 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 525 Medical Devices & Instruments companies, Straumann Holding AG ranks worse than 92.76% on this metric.
The historical rank and industry rank for Straumann Holding AG's Cyclically Adjusted PB Ratio or its related term are showing as below:
XSWX:STMN'
s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 7.83 Med: 16.48 Max: 37.14
Current: 11.12
During the past 13 years, Straumann Holding AG's highest Cyclically Adjusted PB Ratio was 37.14. The lowest was 7.83. And the median was 16.48.
XSWX:STMN's Cyclically Adjusted PB Ratio is ranked worse than 92.76% of 525
companies
in the Medical Devices & Instruments industry
Industry Median: 1.8
vs XSWX:STMN: 11.12
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
Straumann Holding AG's adjusted book value per share data of for the fiscal year that ended in Dec25 was CHF13.550. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is CHF9.68 for the trailing ten years ended in Dec25.
Shiller PE for Stocks: The True Measure of Stock Valuation
Straumann Holding AG (XSWX:STMN) Cyclically Adjusted PB Ratio Explanation
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
Straumann Holding AG Cyclically Adjusted PB Ratio Related Terms
Straumann Holding AG Cyclically Adjusted PB Ratio Historical Data
* Premium members only.
The historical data trend for Straumann Holding AG's Cyclically Adjusted PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Straumann Holding AG Cyclically Adjusted PB Ratio Chart
XSWX:STMN vs ISRG, BDX, MDLN: Cyclically Adjusted PB Ratio Comparison
For the Medical Instruments & Supplies subindustry, Straumann Holding AG's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Straumann Holding AG Cyclically Adjusted PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Straumann Holding AG's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where Straumann Holding AG's Cyclically Adjusted PB Ratio falls into.
Straumann Holding AG Cyclically Adjusted PB Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PB Ratio of 11.12 mean?
Straumann Holding AG (XSWX:STMN) has a Cyclically Adjusted PB Ratio of 11.12 as of Jul. 05, 2026. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Straumann Holding AG and its competitors. This is 33% below median its historical median of 16.48. Over the past decade, Straumann Holding AG's Cyclically Adjusted PB Ratio has ranged from 7.83 to 37.14. According to the industry distribution chart, Straumann Holding AG ranks #487 out of 525 companies in the Medical Devices & Instruments industry, placing it in the top 92.8%.
Is Straumann Holding AG's Cyclically Adjusted PB Ratio too high?
Straumann Holding AG's current Cyclically Adjusted PB Ratio of 11.12 is 33% below median its 10-year median of 16.48. Over the past 10 years, this metric has ranged from a low of 7.83 to a high of 37.14. The Medical Devices & Instruments industry median Cyclically Adjusted PB Ratio is 1.80. Straumann Holding AG's value of 11.12 is 517.8% above this industry median. Based on the distribution chart, Straumann Holding AG ranks #487 out of 525 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Straumann Holding AG has a GF Score™ of 100/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Straumann Holding AG's Cyclically Adjusted PB Ratio compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Straumann Holding AG ranks #487 out of 525 companies for Cyclically Adjusted PB Ratio. This places Straumann Holding AG in the lower half of its industry. The industry median Cyclically Adjusted PB Ratio is 1.80. Straumann Holding AG's value of 11.12 is 517.8% above this benchmark. Historically, Straumann Holding AG's own Cyclically Adjusted PB Ratio has ranged from 7.83 to 37.14 over the past decade. While the company's 10-year median is 16.48 vs. the industry median of 1.80, Straumann Holding AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PB Ratio for a Medical Devices & Instruments company?
The median Cyclically Adjusted PB Ratio among Medical Devices & Instruments companies is 1.80, based on 525 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Straumann Holding AG's current Cyclically Adjusted PB Ratio of 11.12 is 517.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PB Ratio mean?
A high Cyclically Adjusted PB Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Straumann Holding AG and its competitors. For the Medical Devices & Instruments industry, the median Cyclically Adjusted PB Ratio is 1.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Straumann Holding AG's current Cyclically Adjusted PB Ratio is 11.12, which is 33% below median its own 10-year median of 16.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Straumann Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Straumann Holding AG (XSWX:STMN) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF137.24, compared to a current price of CHF107.65 — trading 21.6% below its estimated fair value. The current Cyclically Adjusted PB Ratio is 11.12, which is 33% below median its 10-year median of 16.48 and 517.8% above the Medical Devices & Instruments industry median of 1.80. Straumann Holding AG's overall GF Score™ is 100/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PB Ratio calculated?
Cyclically Adjusted PB Ratio is calculated from a company's financial statements. For Straumann Holding AG (XSWX:STMN), the current Cyclically Adjusted PB Ratio is 11.12 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Straumann Holding AG (XSWX:STMN) Overvalued in 2026?
Based on GuruFocus' analysis, Straumann Holding AG stock appears to be undervalued.
The current stock price of CHF107.65 is trading 21.6% below its estimated GF Value™ of CHF137.24.
GuruFocus considers Straumann Holding AG to be Modestly Undervalued.
Key valuation signals for XSWX:STMN:
Cyclically Adjusted PB Ratio: 11.12 (33% below median its 10-year median of 16.48)
GF Value™: CHF137.24 vs. price of CHF107.65 (21.6% below fair value)
Industry Position: 517.8% above the Medical Devices & Instruments median (#487 of 525)
No single metric tells the full story. See the XSWX:STMN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Straumann is a global leader in tooth replacement and orthodontics solutions. Its line of products includes dental implants, abutments, clear aligners, biomaterials, and computer-aided design/computer-aided manufacturing equipment. The firm's core products are dental implants, and it holds over one third of the CHF 6 billion global market. Originally a pure premium implant player, Straumann entered the value market in 2012 with its acquisition of Neodent. Straumann now accounts for almost half of the global premium market and around 15% of the value market. While its premium product catalog is marketed under Straumann, its value brands include Neodent, Anthogyr, and Medentika as well as other local and regional brands.
100GF Score
Get the complete analysis for XSWX:STMN
Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:STMN has been successfully added to your 
